GLP-1s As A Treatment for Alzheimer's Disease - James Breaks Down the Science

In this episode of the Gillett Health Podcast, James O'Hara, NP , breaks down the latest evidence surrounding

GLP-1 receptor agonists (like semaglutide) and their potential role in Alzheimer's disease and long-term

cognitive health.

While recent clinical trial results show that oral semaglutide does not reverse established Alzheimer's dementia,

could GLP-1s still play a powerful role in preventing cognitive decline?

Key Topics Covered:

Top-line trial results for oral semaglutide in Alzheimer's disease

Observational data showing lower cognitive risk in diabetics on GLP-1s

Changes in the blood biomarker p-tau217

How reducing cravings for sugar, alcohol, and nicotine protects cognitive reserve

Timestamps:

0:00 - Welcome & Introduction